JSR (4185) Q2 2026 earnings summary

Executive summary

• Returned to net profitability for the first time in five half years, with significant improvements in revenue and core operating profit, mainly driven by Electronic Materials (EM).

• Strategic divestments in non-core Life Science (LS) businesses are underway to improve financial structure.

Financial highlights

• FY25 first-half revenue reached ¥211.3 billion, up 11% year-over-year.

• Core operating profit was ¥26.0 billion, a turnaround from a loss of ¥4.4 billion in the prior year.

• Net profit was ¥3.9 billion, compared to a net loss of ¥58.0 billion year-over-year.

• EBITDA improved to ¥43.8 billion from a loss of ¥13.6 billion year-over-year.

Outlook and guidance

• On track to exceed full-year core operating profit target of over ¥30 billion, with 85% progress achieved in the first half.

• Continued growth expected, led by strong EM demand, especially in AI-related sectors.

• Proceeds from divestitures will support debt reduction and financial structure improvements.